Cytovance Biologics has announced the addition of an integrated single-use platform for the manufacturing of plasmid DNA (pDNA) at their facilities in Oklahoma City, OK. Two grades are available (Critical Reagent Grade™, CGMP-grade) in lot sizes from 1g to 50g. One grade is available (R&D-grade) in lot sizes from 1g to 5g.
“Cytovance Biologics is committed in investing additional capabilities and infrastructure to serve our clients and enable them to improve the lives of patients all around the world,” said Yan Wang, Chief Executive Officer of Cytovance Biologics. “With this new platform, our teams will ensure high-quality, fast, and affordable plasmid development and delivery, which will be key to our clients and ultimately benefit the patients.”
“With our years of experience with products of varying biological sources and complexities coupled with the principles of phase-appropriate CGMPs, Cytovance Biologics is uniquely positioned to offer clients the flexible options that are being sought in a robust gene therapy supply chain partner,” said Jesse McCool, Chief Technology Officer of Cytovance Biologics. “Whether our clients need pDNA for early pre-clinical work or for advanced commercial efforts, our team will ensure a cost-effective and robust supply of high-quality plasmids that align with the regulatory expectations across a product’s lifecycle.”